InMed Pharmaceuticals Inc. (INM)

CIK 0001728328 · Healthcare · Drug Manufacturers

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q3-2026 —
Q2-2026 —
Q1-2026 —
FY-2025
Latest FY-2025 —
Q3-2025 —
Q2-2025 —
Q1-2025 —
FY-2024 —
Q3-2024 —
Q2-2024 —
FY-2023
Q1-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Document and Entity Information
Audit Information
—
Statements
Condensed Consolidated Interim Balance Sheets
—
Consolidated Balance Sheets
Condensed Consolidated Interim Balance Sheets (P)
—
Consolidated Balance Sheets (P)
Condensed Consolidated Interim Statements of Operations (unaudited)
—
Condensed Consolidated Statements of Operations Unaudited
—
Consolidated Statements of Operations
Condensed Consolidated Interim Statements of Operations (unaudited) (P)
—
Condensed Consolidated Statements of Shareholders Equity Unaudited
—
Consolidated Statements of Shareholders Equity
Condensed Consolidated Interim Statements of Shareholders Equity (unaudited)
—
Condensed Consolidated Statements of Cash Flows Unaudited
—
Consolidated Statements of Cash Flows
Consolidated Statements of Operations (P)
Condensed Consolidated Interim Statements of Cash Flows (unaudited)
—
Notes
Accounts Payable and Accrued Liabilities
Acquisition
—
Commitments and Contingencies
Corporate Information and Continuing Operations
Cybersecurity Risk Management and Strategy Disclosure
—
Discontinued Operations
—
Impairment of Intangible Assets and Goodwill
—
Income Taxes
—
Insider Trading Arrangements
Intangible Assets
Inventories
Lease Obligations
Pay Vs Performance Disclosure
Property, Equipment and Right of Use (rou) Assets, Net
—
Property, Equipment and Rou Assets, Net
Related Party Transactions
Segment Information
Share Capital and Reserves
Share-based Payments
Significant Accounting Policies
Subsequent Events